EFFICACY AND TOLERABILITY OF JANUS KINASE INHIBITOR TOFACITINIB IN JUVENILE LINEAR SCLERODERMA. CASE SERIES OF 5 PATIENTS.
Our case series showed a significant improvement in skin and joint damage after 12 months of TF therapy in resistant JLSL patients. Further experience with TF is needed to determine its place in the treatment of juvenile scleroderma.
Authors
- О.В. Шпитонкова (ORCID: https://orcid.org/0000-0001-8132-0169)
- М.К. Осминина (ORCID: https://orcid.org/0000-0003-3537-5390)
- S.Kh. Kurbanova (ORCID: https://orcid.org/0000-0003-0509-1055)
- N.S. Podchernyaeva (ORCID: https://orcid.org/0000-0002-7498-1636)
- V. A. Seraya (ORCID: https://orcid.org/0000-0001-9186-0126)
- Nadezhda K. Ziskina (ORCID: https://orcid.org/0009-0002-9057-7649)
- A. A. Skakodub
- A Polyanskaya
- O Batureva
- S Chebusheva
Institutions
- Sechenov University (RU)
Publication Details
- Journal
- PubMed
- Published
- 2025-01-01
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00